Loading...
•
Jun 30, 2021
Cardiff Oncology Q2 2021 Earnings Report
Announced second quarter 2021 results and provided business updates, highlighting clinical program advancements and financial performance.
Key Takeaways
Cardiff Oncology reported its second quarter 2021 results, highlighting advancements in its clinical programs, particularly in KRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. The company's leadership was strengthened with new appointments, and the financial results indicated a strong cash position of approximately $140 million.
Lead clinical program in KRAS-mutated metastatic colorectal cancer continues to show robust response and progression-free survival.
First patient dosed in Phase 2 study for metastatic pancreatic ductal adenocarcinoma.
Appointed new CMO and CFO, and added two new board members with expertise in drug development and financial strategy.
Company included as a member of FTSE Russell Indexes.
Revenue by Segment
Forward Guidance
Cardiff Oncology anticipates continued progress in its clinical trials and efforts to expand onvansertib's pipeline of indications. The company expects a steady cadence of catalysts over the coming months, driven by its strong cash position and recent progress in clinical and preclinical programs.
Positive Outlook
- Advancements in KRAS-focused programs for metastatic pancreatic ductal adenocarcinoma (mPDAC).
- Promising data from the lead KRAS-mutated metastatic colorectal cancer program.
- Expectations for continued progress in castrate-resistant prostate cancer trial.
- Advancements in efforts to expand onvansertib’s pipeline of indications.
- Strong cash position to support ongoing and future clinical trials.
Challenges Ahead
- Clinical trials involve a lengthy and expensive process with an uncertain outcome.
- Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks.
- Risks related to business interruptions, including the outbreak of COVID-19 coronavirus.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...